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Abstract
Background: Previous studies have demonstrated that neonatal manipulation of oxytocin (OT)
has effects on the expression of estrogen receptor α (ERα) and the central production of oxytocin
observed in juveniles (at weaning, 21 days of age). The goal of this study was to determine whether
the effects of neonatal manipulation of OT last into adulthood, and if the effects differ from those
observed during the early postnatal period. On the first day of life, prairie voles (Microtus
ochrogaster) received one of three doses of OT (High, 3 µg; Med, 0.3 µg; Low, 0.03 µg), an OT
antagonist, or isotonic saline. Another group was handled, but not injected. Then as adults, brains
were collected, sectioned, and stained for ERα or OT using immunocytochemistry.
Results: In females, treatment with OT increased the expression of ERα immunoreactivity in the
ventral lateral septum (0.03 µg) and the ventromedial nucleus of the hypothalamus and central
amygdala (0.3 µg). In males, OT antagonist increased ERα expression in the bed nucleus of the stria
terminalis. There was no apparent effect of OT on the number of cells producing OT in the
paraventricular nucleus of the hypothalamus.
Conclusion:  The current results suggest that neonatal manipulation of OT has long-term
organizational effects on the expression of ERα in both males and females. The lack of effect on
OT neurons in the paraventricular nucleus suggests that some developmental effects of OT
previously observed in weanlings do not persist into adulthood. Developmental effects of OT on
ERα patterns were sexually dimorphic, dose-dependent, and site-specific.
Background
Recent studies indicate that during the neonatal period
oxytocin (OT) has an organizational effect within the
CNS. Neonatal manipulation of OT affects neuronal activ-
ity, as indicated by the expression of c-Fos in neonates [1],
alters the number of OT neurons in the paraventricular
nucleus of the hypothalamus (PVN) of weanlings [2], and
the distribution of estrogen receptor alpha (ERα) in wean-
lings [3]. The effects of neonatal manipulation of OT are
sexually dimorphic and site specific [1-3]. Given that neo-
natal manipulation of OT affects mechanisms that regu-
late physiological and behavioral responses it is not
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surprising that neonatal manipulations also affect a vari-
ety of behaviors, many of which occur in adults [4-7].
Neonatal manipulations of OT affect behaviors such as
mating bout frequency [4], alloparental behavior [8], and
behavioral reactivity to social isolation [9]. Aside from a
recent report on developmental effects of OT on the pitu-
itary in adults [10], the effects of early exposure to OT on
the CNS have been characterized primarily during the
early postnatal development period up to and including
weaning [2,3]. Much remains to be known about the
developmental effects of OT on the adult CNS. Therefore
one of the goals of this study was to determine the effects
of neonatal manipulation of OT on the production of OT
in the PVN and the central distribution of ERα over a
longer period of time. Previous studies of the effects on
neonatal manipulation of OT have used a single dose of
OT (3 µg), and while these studies have produced signifi-
cant results the dose is pharmacological. Although no
data are available on endogenous plasma OT levels in
pups, data from adults suggest that a dose of 3 µg likely
results in very high OT levels as it is 4 orders of magnitude
higher than plasma concentrations in adult prairie voles
[11]. Thus, a second objective was to determine whether
developmental effects are also observed with lower doses.
Below, we report the developmental effects of neonatal
administration of OT or antagonist on central patterns of
ERα and OT neurons as observed in adult male and
female prairie voles.
Results
Treatment effects were site-specific, sexually dimorphic,
and dose-dependent. In males, treatment with OT antag-
onist (OTA) increased ERα-immunoreactivity (IR) in the
bed nucleus of the stria terminalis (BST; P < 0.05) (Fig 1
and 2). In females, treatment with Low OT (0.03 µg)
resulted in a significant increase in ERα-IR in the ventral
lateral septum (LSV), while Med OT (0.3 µg) increased
ERα-IR in the ventromedial nucleus of the hypothalamus
(VMH; P < 0.05) and the central amygdala (CeA; P < 0.05)
(Fig 1 and 2). There were no apparent treatment effects in
the medial preoptic area (MPOA), medial amygdala
(MeA), central amygdala (CeA), or arcuate (ARC) in either
males or females. However, in males, there was a tendency
for OTA to increase ERα-IR in the ARC (P < 0.06). In con-
trast to ERα-IR, there was no treatment effect on the
number of OT-IR cells in the PVN or supraoptic nucleus
(SON) of the hypothalamus in either males or females
(Fig 3).
Discussion
Previous studies have demonstrated that neonatal manip-
ulation of OT affects the central production of OT [2] and
the number and distribution of ERα-IR neurons [3] dur-
ing the neonatal period, at least up to 21 days after birth.
Other studies have shown that neonatal manipulation of
OT can have long-term behavioral effects that are
expressed a week to months after the initial treatment
such as changes in response to social stimuli or reductions
in parental care [4,8,9,12]. Taken together these studies
predict that the early effects of OT on the organization of
the CNS are long-term, and should not only be apparent
in neonates, but also in adults. This is supported by a
recent study that found alterations in OT content of the
pituitary of adult rats resulting from neonatal OT and
OTA [10]. The results from our study further support the
prediction that neonatal manipulation of OT can alter the
adult CNS, as neonatal manipulation of OT on the day of
birth affected ERα-IR in both males and females. The
results from this study extend the previous findings indi-
cating that the effects of increased or decreased OT during
the neonatal period on the CNS are long term. The organ-
izational effects of OT vary with age and are dose-depend-
ent and sexually dimorphic. The results also suggest that
interactions between OT and ERα during development are
important in the regulation of behavior later in life.
Developmental effects of OT vary with age and dose
Previous studies, using c-Fos as an indicator of neural acti-
vation, demonstrated that neonatal manipulation of OT
has immediate effects on the CNS [1]. It is unclear
whether the immediate and developmental effects of neo-
natal OT or OTA result from direct effects on the CNS or
result from indirect effects, perhaps through an afferent
feedback response to OT stimulation of peripheral organs.
If the differential neural activation seen in response to OT
or OTA treatment results from direct effects of OT on the
brain, there is good reason to expect it to have develop-
mental effects. There is ample opportunity for OT to affect
the organization of the CNS as OT receptor (OTR) distri-
butions are still developing during the early postnatal
period [13]. The opportunity for OT to alter the CNS also
is greater than that predicted by the adult distribution of
OTR as some regions such as the cingulate cortex and the
medial mammilary nucleus express OTR during the neo-
natal period but not during adulthood [14]. Recent work
has demonstrated that developmental effects of neonatal
OT are evident as late as day 21 [2,3]. Neonatal treatment
with either High OT (3 µg) or OTA increased the number
of OT-IR cells in the PVN of females at day 21 [2], however
the present results indicate these effects do not last into
adulthood. This is somewhat surprising given that in rats,
the same neonatal manipulations alter OT content of the
pituitary in adulthood [10], however the regulation of the
oxytocinergic system is expected to differ between species
showing a high degree of social interactions outside of
copulation and species with more limited social interac-
tions such as the rat. Additionally, pituitary OT content
and number of OT neurons in the PVN could be differen-
tially regulated. It is possible that alterations in OT-IR
were not observed in adult prairie voles because someBMC Neuroscience 2007, 8:71 http://www.biomedcentral.com/1471-2202/8/71
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aspect of physiological and neural maturation from wean-
ling to adult reduces any differences in OT production.
Alternatively, differences in OT production might be lost
as a result of the changing social environment, from a nest
with contact with parents to housing with a single sibling.
Finally, an increased sample size could reveal treatment
effects but, if so, would suggest the effects are not as robust
as those seen at day 21.
OT does, however, have lasting developmental effects on
the distribution and number of ERα-IR neurons. Both
neonatal OT and OTA altered ERα-IR in adult females,
however the regions affected differed from those reported
in 21-day old females. In day 21 females, High OT
increased ERα-IR in the VMH and OTA decreased ERα-IR
in the MPOA [3] but only lower doses, Low OT and Med
OT, had effects on ERα-IR lasting into adulthood. The
Developmental effects of oxytocin on central ERα Figure 1
Developmental effects of oxytocin on central ERα. The mean number of cells expressing ERα-IR in females and males in 
(a) the ventral lateral septum (LSV); (b), bed nucleus of the stria terminalis (BST); (c) ventromedial nucleus of the hypothalamus 
(VMH); and (d), the central amygdala (CeA). The effect of neonatal manipulation of OT was sexually dimorphic, dose-depend-
ent, and site-specific. In females, treatment with OT increased ERα-IR in the LSV (a), VMH (c) and CeA (d). In males, OTA 
increased ERα-IR in the BST (c). Low, Med, and High treatments were single injections of 0.03 µg OT, 0.3 µg OT, or 3 µg OT, 
respectively. * = significantly different from CON.BMC Neuroscience 2007, 8:71 http://www.biomedcentral.com/1471-2202/8/71
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OT-IR in the hypothalamus Figure 3
OT-IR in the hypothalamus. The mean number of cells expressing OT-IR in females and males in (a) the paraventricular 
nucleus of the hypothalamus (PVN) and (b) the supraoptic nucleus (SON). There was no significant treatment effect in either 
nucleus.
Central ERα Figure 2
Central ERα. Photomicrographs (100x) of ERα-IR in the ventromedial nucleus of the hypothalamus (VMH) of females from 
the (a) CON and (b) Med OT groups, and in the bed nucleus of the stria terminalis (BST) of males from the (c) CON and (d) 
OTA groups. The black scale bar represents 200 µm.BMC Neuroscience 2007, 8:71 http://www.biomedcentral.com/1471-2202/8/71
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observed by Yamamoto et al. [3], with both increasing
ERα-IR, however the LSV and VMH were affected, not the
MPOA. In males, effects also varied depending upon age.
Neonatal treatment with OTA had no apparent effects in
males at day 21, but by adulthood increases in ERα were
evident in the BST.
It is not surprising that the observable effects of neonatal
manipulation of OT vary with age. Development of neu-
roendocrine systems, both in terms of production of neu-
ropeptides and sensitivity to hormones, can occur over a
relatively long period of time [e.g., [15]], thus the organi-
zational effects hormones on various brain regions or
behaviors might be apparent at different time points. For
example, it is clear that in prairie voles, the distribution of
ERα continues to change during the second and third
postnatal weeks [3] and changes may occur beyond that
point. Additionally, some sexual maturation occurs
between day 21 and day 60–90, the two ages for which
data are available. It is expected that during intermediate
ages there are some additional changes in the neuroendo-
crine system and the developmental effects of OT might
be manifested differently after sexual maturation. Dose-
dependent effects of OT also were expected given that this
is common for many biologically active chemicals and
hormones. In order to put the dose-dependent effects
observed here into context, future studies measuring
endogenous levels of OT and natural variation in central
OT will be necessary.
Sexually dimorphic effects of neonatal OT/OTA
Sexually dimorphic responses to neonatal OT/OTA is con-
sistent with previous studies of the developmental effects
of OT on both neuroanatomy [2,3,10] and behavior
[8,9,16]. Most studies reporting data for both sexes have
found females to be more sensitive than males to the
developmental effects of OT on neuroanatomy and
behavior [2,3,9,12,16]. Sexually dimorphic effects on
ERα-IR, in particular, were expected based on sexual
dimorphism in ERα evident in adult prairie voles [17,18]
and on differences in ontogeny of the ERα distribution in
males versus females [3,19,20]. In the present study,
developmental effects of OT were observed in both sexes
but the regions and the direction of effect were different
for males and for females. In males, OTA increased ERα-
IR while in females, OT increased ERα-IR. In light of the
regions affected, the direction of response fits with behav-
ioral traits associated with manipulation of OT. OTA
increased ERα-IR in the BST of males. Behavioral data sug-
gests that OTA treatment might generally increase anxiety
or aggression [8,9] and it has been hypothesized that an
increase in ERα in the BST is correlated with increased
aggression [21].
OT regulation of steroid sensitivity
In many species, the effects of OT are steroid-dependent
and estrogen increases sensitivity to OT [22-25]. However,
in highly social species, such as the prairie vole, it appears
that OT regulates sensitivity to steroids. Such an interac-
tion is in keeping with the events leading up to copula-
tion; prairie vole females require a prolonged period of
social contact with a male before becoming sexually
receptive [26]. Social contact is regulated by OT [27] while
E regulates sexual receptivity, thus in a species requiring
social contact prior to copulation, OT affects sensitivity to
E [28]. Additionally, evidence for OT regulation of E sen-
sitivity come from studies of human breast cancer cell
lines in which OT down regulates both ERα mRNA and
ERα protein expression [29]. Furthermore, variations in
maternal care that are associated with increased OTR also
increase ERα expression in the MPOA [30,31]. It is
becoming increasingly clear that neuropeptides interact
with steroids to regulate behavior (reviewed in [21]) and
the results of this study indicate one more way in which
neuropeptides might alter sensitivity to steroids. The fact
that manipulations of OT early in life alter ERα-IR in
adulthood, suggests that OT might not simply regulate
sensitivity to E through activational effects, but that organ-
izational effects of OT produce lasting changes in sensitiv-
ity to steroids. Our data provide an additional mechanism
by which neuropeptides might act to alter or regulate sen-
sitivity to steroids. This in turn has the potential to alter
sociosexual behaviors mediated by OT and ERα.
Conclusion
The results from this study advance findings from the pre-
vious studies that demonstrated organizational effects of
OT during the neonatal period on ERα and OT expres-
sion. First, the effects on ERα expression/organization are
long-term, being expressed in adulthood. Second, the
effects were not only sexually dimorphic, but the observed
effect changed with age. Significant changes in ERα
expression in males occurred at some point between
weaning and adulthood while in females, significant
changes were observed at both ages. In contrast to the
observed organizational effects on ERα, the effect on OT
neurons in the PVN reported in juveniles were no longer
observed in adults, suggesting that changes to the oxytoc-
inergic system are temporary. Third, alterations in ERα-IR
were site-specific and likely to be behaviourally relevant.
For example, antagonist increased ERα-IR in the BST and
high levels of ERα are associated with decreases in social
behavior, as is blockade of OTR early in life. There is
mounting evidence for the role of OT in the development
of the CNS, perhaps mediating social behavior later in life.
The data reported here provide further support for this
hypothesis. More important, these data demonstrate that
a neuropeptide can act during developmental periods to
affect sensitivity to steroids later in life and indicates theBMC Neuroscience 2007, 8:71 http://www.biomedcentral.com/1471-2202/8/71
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importance of considering both neuropeptides and ster-
oids in examining developmental effects of hormones on
subsequent social behavior and underlying neuroanat-
omy.
Methods
Husbandry and Treatments
Animals used in this study were laboratory-reared prairie
voles that originated from wild stock trapped near
Urbana, Illinois. Animals were housed under a 14:10
light:dark cycle and provided high fiber rabbit chow and
water ad libitum. On the day of birth pups were sexed and
marked for identification. Pups were given a single intra-
peritoneal injection (50 µl) of isotonic saline (SAL; vehi-
cle control), one of three doses of OT, 3 µg
(approximately 1 µg/g; High OT), 0.3 µg (approximately
0.1 µg/g; Med OT), 0.03 µg (approximately 0.01 µg/g;
Low OT), or 0.3 µg (approximately 0.1 µg/g) OT antago-
nist (OTA; [d(CH2)5, Tyr(Me)2, Orn8]-Vasotocin; Bachem,
Belmont, CA). An additional group was handled but not
injected (HAN). The doses for High OT and for OTA were
chosen because there is extensive literature indicating that
during the neonatal period these doses can affect the CNS
immediately after injection [1] and have developmental
effects on a variety of physiological and behavioral
responses in both male and female rats and prairie voles
[2,4-9]. A relatively low dose of OTA was chosen because
the antagonist binds OTR more effectively than OT, with
an affinity for OTR greater than 10 times that of the natu-
ral ligand [32] and this same dose has been used in mul-
tiple other studies [2,3,7,9]. Injections were
intraperitoneal because of the disruptive nature of central
injections. Previous work demonstrated that the OTA
dose and High OT cause differential c-Fos-IR in neonates,
indicating that an i.p. route does affect the CNS [1]. How-
ever, it is unknown whether the immediate effects of these
treatments are direct or indirect. It is possible that OT and/
or OTA cross the blood-brain barrier as it is not yet fully
developed in the first 2 postnatal weeks [33] and some
data indicate that small neuropeptides can cross the
blood-brain barrier [34].
Pups were assigned to treatment groups randomly with
the restriction that within each litter there was at least one
control (SAL or HAN) and one experimental (OT or OTA)
pup. No treatment was represented more than once per
sex per litter. Pups were kept warm during the injections
using a heat lamp and returned as a group to the home
cage within 10 min. Pups were weaned at 21 days of age
and then housed in same-sex sibling pairs until brains
were collected (see below) between 60 and 90 days of age;
n  = 6 per treatment per sex. Animals were housed in
accordance with the USDA and NIH guidelines and meas-
ures were taken to minimize pain and discomfort. All pro-
cedures were approved by the University of Illinois at
Chicago Animal Care and Use Committee.
Tissue collection and labelling of ERα and OT neurons
The following is a brief description of tissue collection and
immunocytochemistry; for complete details see [17] for
ERα and [2] for OT. All tissue was collected between 3–5
hr after lights on. Animals were deeply anaesthetized
using a combination of Ketamine and Xylazine and then
decapitated. Brains were removed and fixed using a spin-
ning immersion technique [35] with 4% paraformalde-
hyde and 5% acrolein in 0.1 M KPBS (pH 7.6). After 4 hr
in fixative (fix was refreshed at 2 hr) brains were removed
and stored in 25% sucrose at 4°C until sectioning at 30
µm on a freezing sliding microtome. Free-floating sections
were then stored in cryoprotectant [36] until processed
using standard ABC (avidin:biotinylated enzyme com-
plex) immunocytochemistry.
Sections were rinsed in 0.05M KPBS and then incubated at
room temperature in 1% sodium borohydride. Sections
were again rinsed in KPBS and then incubated in primary
antibody, rabbit ERα polyclonal antibody (Upstate USA,
Charlottesville, VA anti-ERα C1355) at a dilution of
1:8,000 in 0.05M KPBS-0.4% TritonX-100 or anti-OT
(generously provided by Dr. Mariana Morris) at a dilution
of 1:100,000 for 1 hr at room temperature and then for 48
hr at 4°C. The ERα antibody binds both free and bound
receptors, minimizing variation due to endogenous ster-
oid levels [37]. The antibody was generated against the
last 15 C-terminal amino acids of the rat ERα protein, a
region that shares no homology with ERβ. The specificity
of this antibody was tested by omitting the primary anti-
body from the ICC procedure and by performing ICC after
pre-adsorption with the synthetic peptide (10x the con-
centration of the antibody). Tests of specificity are also
detailed in Cushing and Wynne-Edwards [17]. Following
incubation in the primary, tissue was rinsed and then
incubated for 1 hr at room temperature in biotinylated
goat, anti-rabbit IgG (1:600 dilution in KPBS-0.4% Tri-
tonX-100; Vector Laboratories, Burlingame, CA). Sections
were again rinsed prior to being incubated for 1 hr at
room temperature in an avidin-biotin peroxidase com-
plex (Vectastain ABC kit-elite pk-6100 standard, 4.5 µl A
and 4.5 µl B per 1 ml solution; Vector Laboratories)
diluted in KPBS-0.4% TritonX-100. Sections were rinsed
with KPBS followed with rinses using 0.175M sodium ace-
tate. Finally, ERα or OT was visualized by incubating in a
nickel sulfate-diaminobenzidine chromogen (ERα) or a
diaminobenzidine (OT) solution for 15 min. Sections
were rinsed and then mounted on subbed glass slides, air
dried, dehydrated in ascending ethanol solutions, cleared
in Histoclear, and coverslipped using Histomount.BMC Neuroscience 2007, 8:71 http://www.biomedcentral.com/1471-2202/8/71
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Statistical Analysis
For each brain region, the number of cells expressing ERα-
or OT-immunoreactivity (IR) were counted bilaterally
using IP Lab (Scanalytics, Inc, Fairfax, VA) image analysis
software at 40× magnification and then averaged. Slides
were coded and then scored by an observer who was blind
to the treatment condition of the subject. Regions ana-
lyzed for ERα-IR included the ventral lateral septum
(LSV), medial preoptic area (MPOA), bed nucleus of the
stria terminalis (BST), arcuate nucleus (ARC), ventrome-
dial nucleus of the hypothalamus (VMH), the central
amygdala (CeA), and the medial amygdala (MeA). Efforts
were made to score similar sections of each region for all
subjects by using the shape of the nucleus, landmarks
such as the optic tracts, and referencing the mouse and rat
brain atlases [38,39]. These areas were chosen because
they are involved in regulating a variety of aspects of
reproduction and social behavior, behaviors that have
been reported to respond to neonatal manipulation of OT
[7,4,8,16]. OT-IR cells were counted in the paraventricular
nucleus of the hypothalamus (PVN) and in the supraoptic
nucleus (SON), which are the two primary brain regions
that produce OT.
Because there was no difference between the vehicle con-
trol (SAL) and the handling control (HAN) in ERα-IR in
either sex or any region, for the purpose of analysis these
were grouped into a single control group (CON).
Although multiple doses of OT were used, the apriori goal
of this study was to determine the effect of treatment rela-
tive to controls and not to generate a dose response curve.
Therefore, treatment differences were compared against
the control group using a Fisher's Least Significant Differ-
ence (LSD) test for each sex by region. A Fisher's LSD was
used because it is the recommended statistical approach
for apriori comparisons [40]. Sexes were analyzed sepa-
rately because apriori we expected there to be significant
differences between males and females based on previ-
ously published studies of developmental effects of OT
[2,3,8,9,16]. Results were considered significant if P  <
0.05.
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